• Cancer is a complex disease that is associated with multiple redundant ligand-receptor interactions, which signal through different, often overlapping, cellular pathways. It has been demonstrated that cancer therapy with mAbs solely targeting a single antigen has limitations. Blockade of multiple targets, or different epitopes on a single target, should result in improved therapeutic efficacy. However, combination therapy requires substantial investment of resources for manufacturing, clinical studies, and ultimately may bare unacceptably high costs for healthcare systems.  
  • The main alternative to combination therapy, dual targeting with bispecific antibodies, has recently emerged in oncology and in many instances has proven to be synergistic. This synergistic activity, deriving from targeting two antigens with a bispecific antibody, should lead to higher efficacy, and safety, and may result in advantageous new biological effects unattainable by monospecific targeting.
  • In cancer treatment, bispecific antibodes are considered one of the most promising next-generation antibody modalities. Bispecific antibodies are one of the fastest growing classes of drugs currently being developed in the clinic. This class of antibodies possesses increased avidity and thus is expected to be more potent and efficacious than combinations of monospecific antibodies. Bispecific antibodies are also expected to possess lower off-target binding, and thus reduced side-effects, relative to monospecific antibodies. Therefore, bispecific antibodies are poised to increase a therapeutic index (increased efficacy and safety) compared to monospecific antibodies or their combinations.
  • The discovery that immune system can potently destroy cancer cells, if inhibitory signals from cancer cells are blocked, revolutionized the treatment of cancer. Numerous “checkpoint” inhibitors are approved for the treatment of various cancers such as melanoma, lung, kidney, bladder, head-and-neck cancers, as well as Hodgkin Lymphoma. Such approaches dramatically changed the course of many cancers and for some patients achieved cures of previously incurable diseases while extending lives of other patients.
  • BIOMUNEX is capitalizing on all these novel advancements in the treatment of cancer and is building a portfolio of innovative therapeutics by combining the power of checkpoint inhibitors with the power of bispecific antibodies.